Почетна › Рак дојке › Тенеси › Nashville
Kliničke studije za Рак дојке u gradu Nashville, TN
78 studija za Рак дојке traži učesnike na lokacijama u gradu Nashville i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Тражи се учесникФаза 2
- SCRI Oncology Partners ( Site 7000), Nashville
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Тражи се учесникФаза 1/2
- Greco Hainsworth Center for Research Tennessee Oncology, Nashville
- SCRI Oncology Partners, Nashville
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Тражи се учесникФаза 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Тражи се учесникФаза 2
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Тражи се учесникФаза 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Тражи се учесникФаза 1/2
- Tennessee Oncology PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Тражи се учесникФаза 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Тражи се учесник
- Vanderbilt, Nashville
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Тражи се учесникФаза 3
- Tennessee Oncology, PLLC, Nashville
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Тражи се учесникФаза 3
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Тражи се учесникФаза 3
- Vanderbilt University Medical Center, Nashville
E-Mindfulness Approaches for Living After Breast Cancer
Тражи се учесникФаза 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Тражи се учесникФаза 2
- Tennessee Oncology, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Тражи се учесникФаза 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Тражи се учесникФаза 2
- SCRI Oncology Partners, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Тражи се учесникФаза 2
- SCRI Oncology Partners, Nashville
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Тражи се учесникФаза 3
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0068), Nashville
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Тражи се учесникФаза 1
- SCRI Oncology Partners, Nashville
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Тражи се учесникФаза 3
- Tennessee Oncology, Nashville
Cancer Pain Management Using a Web-based Intervention
Тражи се учесник
- Vanderbilt University, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Tennessee Oncology PLLC, Nashville
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Тражи се учесникФаза 1
- Sarah Cannon Research Institute, Nashville
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Тражи се учесникФаза 2
- Sarah Cannon Research Institute (Nashville), Nashville
- Vanderbilt University Medical Center, Nashville
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Тражи се учесникФаза 1/2
- Sarah Cannon Nashville, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 2
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Тражи се учесникФаза 1/2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Tennesse Oncology - Mt. Juliet Clinic, Mount Juliet · 15 ми удаљено
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1
- SCRI Oncology Partners - Nashville, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Тражи се учесникФаза 1/2
- Tennessee Oncology, Nashville
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Тражи се учесникФаза 3
- Research Site, Nashville
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Тражи се учесникФаза 3
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- и још 1
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Тражи се учесникФаза 3
- SCRI Oncology Partners, Nashville
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Тражи се учесникФаза 1
- Scri Oncology Partners, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Sarah Cannon Research Institute, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Тражи се учесникФаза 1
- Sarah Cannon Research Institute, Nashville
A Study of PHST001 in Advanced Solid Tumors
Тражи се учесникФаза 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- Sarah Cannon Research Institute, Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Тражи се учесникФаза 1
- SCRI Oncology Partners, Nashville
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Тражи се учесникФаза 1/2
- SCRI Oncology Partners, Nashville
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Тражи се учесникФаза 2
- Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Тражи се учесникФаза 1
- Research Site, Nashville
IKS014 in Advanced Solid Tumors That Express HER2
Тражи се учесникФаза 1
- Tennessee Oncology, Nashville
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Тражи се учесникФаза 3
- Research Site, Nashville
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Тражи се учесникФаза 1/2
- Vanderbilt Ingram Cancer Center, Nashville
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Тражи се учесникФаза 3
- Clinical Trial Site, Nashville
- Clinical Trial Site, Mount Juliet · 15 ми удаљено
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1
- Sarah Cannon Research Center, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Тражи се учесникФаза 1
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Тражи се учесникОпсервациона студија
- Nashville General, Nashville
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Тражи се учесникФаза 1
- Sarah Cannon Research Institute/SCRI, Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Тражи се учесникФаза 1/2
- SCRI Oncology Partners, Nashville
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Тражи се учесникФаза 2
- Vanderbilt Cancer Center, Nashville
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Vanderbilt-Ingram Cancer Center, Nashville
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Тражи се учесникФаза 2
- Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville
- SCRI Oncology Partners, Nashville
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Тражи се учесникФаза 3
- SCRI Oncology Partners, Nashville
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Тражи се учесникФаза 2
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Investigative Site #102, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Sarah Cannon Research Institute, Nashville
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Тражи се учесникФаза 1/2
- SCRI Oncology Partners, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Тражи се учесникФаза 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Тражи се учесникФаза 1/2
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Тражи се учесникРана фаза 1
- Vanderbilt University Medical Center, Nashville
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Тражи се учесникФаза 2
- Vanderbilt University, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Тражи се учесник
- Vanderbilt-Ingram Cancer Center, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Тражи се учесникФаза 2
- Vanderbilt-Ingram Cancer Center, Nashville
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Тражи се учесникФаза 3
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Тражи се учесникФаза 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Тражи се учесникФаза 1
- Sarah Cannon Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Tennessee Oncology, PLLC, Nashville
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Тражи се учесникФаза 2
- SCRI Oncology Partners, Nashville
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Тражи се учесникФаза 1
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Тражи се учесникФаза 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Tennessee Oncology, Nashville
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Тражи се учесникФаза 1
- Tennessee Oncology, Nashville
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Тражи се учесникОпсервациона студија
- Nashville Breast Center, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Тражи се учесникФаза 1/2
- SCRI Oncology Partners, Nashville
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Тражи се учесникФаза 1
- SCRI Oncology Partners, Nashville
Studije za Рак дојке u drugim gradovima
- New York City, NY144 студија
- Houston, TX126 студија
- Boston, MA110 студија
- Los Angeles, CA73 студија
- Edison, NJ70 студија
- Queens, NY67 студија
- Durham, NC63 студија
- St. Louis, MO63 студија
- Chicago, IL59 студија
- Dallas, TX54 студија
- Philadelphia, PA51 студија
- Arlington, VA50 студија
Ostale studije u gradu Nashville
- Немалоклетни карцином плућа97 студија
- Метастатски карцином69 студија
- Колоректални карцином67 студија
- Рак (све врсте)65 студија
- Рак јајника50 студија
- Плоскоклеточни карцином главе и врата43 студија
- Рак простате40 студија
- Рак панкреаса39 студија
- Рак плућа39 студија
- Карцином ендометријума38 студија
- Меланом34 студија
- Рак бешике31 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.